These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33578449)

  • 1. An insight into the role of telmisartan as PPAR-γ/α dual activator in the management of nonalcoholic fatty liver disease.
    Devan AR; Nair B; Kumar AR; Nath LR
    Biotechnol Appl Biochem; 2022 Apr; 69(2):461-468. PubMed ID: 33578449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
    Ezhilarasan D
    Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.
    Chen H; Tan H; Wan J; Zeng Y; Wang J; Wang H; Lu X
    Pharmacol Ther; 2023 May; 245():108391. PubMed ID: 36963510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review.
    Borém LMA; Neto JFR; Brandi IV; Lelis DF; Santos SHS
    Hypertens Res; 2018 Jun; 41(6):394-405. PubMed ID: 29636553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
    Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RLA8-A New and Highly Effective Quadruple PPAR-
    Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
    J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
    Honda A; Ishii I
    Yakugaku Zasshi; 2022; 142(12):1335-1343. PubMed ID: 36450511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
    Gao M; Ma Y; Alsaggar M; Liu D
    AAPS J; 2016 Jul; 18(4):1023-31. PubMed ID: 27125895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease.
    Li Z; Xu Y; Cai Z; Wang X; Ren Q; Zhou Z; Xie R
    Bioorg Chem; 2020 Jun; 99():103803. PubMed ID: 32251945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.
    Grobbee EJ; de Jong VD; Schrieks IC; Tushuizen ME; Holleboom AG; Tardif JC; Lincoff AM; Schwartz GG; Castro Cabezas M; Grobbee DE
    PLoS One; 2022; 17(11):e0277706. PubMed ID: 36378671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
    Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
    Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
    Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
    Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W
    Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.